Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine

Journal of Analytical Toxicology

Volumn 20, Issue 6, 1996, Pages 369-378

  Kuhlman Jr , James J ^a   Lalani, Shairose ^a   Magluilo Jr , Joseph ^a   Levine, Barry ^a   Darwin, William D ^b   Johnson, Rolley E ^b,c   Cone, Edward J ^b  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; DRUG METABOLITE; NORBUPRENORPHINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BUCCAL DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; OPIATE ADDICTION; SUBLINGUAL DRUG ADMINISTRATION; TANDEM MASS SPECTROMETRY;

EID: 0029839206     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/20.6.369     Document Type: Article

References (26)

1. th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., L.S. Harris, Ed., U.S. Department of Health and Human Services, Rockville, MD. Natl. Inst. Drug Abuse Res. Monogr. Ser. 153: 158 (1995).
2. S.L. Walsh, K.L. Preston, M.L. Stitzer, E.J. Cone, and G.E. Bigelow. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55: 569-80 (1994).
3. D.R. Jasinski, J.S. Penvick, and J.D. Griffith. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry 35: 501-16 (1978).
4. N.K. Mello and J.H. Mendelson. Buprenorphine suppresses heroin use by heroin addicts. Science 207: 657-59 (1980).
5. N.K. Mello, J.H. Mendelson, and J.H. Kuehnle. Buprenorphine effects on human heroin self-administration: an operant analysis. J. Pharmacol. Exp. Ther. 223: 30-39 (1982).
6. R.E.S. Bullingham, H.J. McQuay, E.J.B. Porter, M.C. Allen, and R.A. Moore. Sublingual buprenorphine used postoperatively: Ten hour plasma drug concentration analysis. Br. J. Clin. Pharm. 13: 665-73 (1982).
7. W.K. Bickel, M.L. Stitzer, G.E. Bigelow, I.A. Liebson, D.J. Jasinski, and R.E. Johnson. A clinical trial of buprenorphine: comparison with methadone in detoxification of heroin addicts. Clin. Pharmacol. Ther. 43: 72-78 (1988).
8. R.E. Johnson, E.J. Cone, J.E. Henningfield, and P.J. Fudala. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin. Pharmacol. Ther. 46: 335-43 (1989).
9. P.J. Fudala, J.H. Jaffe, E.M. Dax, and R.E. Johnson. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin. Pharmacol. Ther. 47: 525-34 (1990).
10. R.E. Johnson, J.H. Jaffe, and P.J. Fudala. A controlled trial of buprenorphine treatment for opioid dependence. J. Am. Med. Assoc. 267: 2750-55 (1992).
11. E.C. Strain, M.L. Stitzer, I.A. Liebson, and G.E. Bigelow. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry 151: 1025-30 (1994).
12. R.E.S. Bullingham, H.J. McQuay, R.A. Moore, and M.R.D. Bennett. Buprenorphine kinetics. Clin. Pharmacol. Ther. 28: 667-72 (1980).
13. S.T. Ho, J.J. Wang, and W. Ho. Determination of buprenorphine by high-performance liquid chromatography with fluorescence detection: application to human and rabbit pharmacokinetic studies. J. Chromatogr. 570: 339-50 (1991).
14. K.T. Olkkola, E.L. Maunuksela, and R. Korpela. Pharmacokinetics of intravenous buprenorphine in children. Br. J. Clin. Pharm. 28: 202-204 (1989).
15. P.J.Q. Watson, H.J. McQuay, R.E.S. Bullingham, M.C. Allen, and R.A. Moore. Single dose comparison of 0.3 mg and 0.6 mg of intravenous buprenorphine given postoperatively: clinical effects and plasma concentrations. Br. J. Anaesth. 54: 37-43 (1982).
16. R.E.S. Bullingham, H.J. McQuay, D. Dwyer, M.C. Allen, and R.A. Moore. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br. J. Clin. Pharm. 12: 117-22 (1981).
17. J.E. Olley and G.K.L. Tiong. Plasma levels of opioid material in man, following sublingual and intravenous administration of buprenorphine: exogenous/endogenous opioid interaction? J. Pharm. Pharmacol. 40: 666-67 (1988).
18. J.J. Kuhlman, Jr., J. Magluilo, Jr., E.J. Cone, and B. Levine. Simultaneous assay of buprenorphine and norbuprenorphine by negative chemical ionization tandem mass spectrometry. J. Anal. Toxicol. 20: 229-35 (1996).
19. W.B. Pickworth, R.E. Johnson, B.A. Holicky, and E.J. Cone. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin. Pharmacol. Ther. 55: 570-79 (1993).
20. M. Reisinger. Buprenorphine as a new treatment for heroin dependence. Drug Alcohol Depend. 16: 257-62 (1985).
21. S.S.W. Seow, A.J. Quigley, K.F. Ilett, L.J. Dusci, G. Swensen, A. Harrison-Stewart, and L. Rappaport. Buprenorphine: A new maintenance opioid? Med. J. Aust. 144: 407-11 (1986).
22. T.J. Kosten and H.D. Kleber. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci. 42: 635-41 (1988).
23. T.R. Kosten, R. Schottenfeld, D. Ziedonis, and J. Falcioni. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181: 358-64 (1993).
24. R.E. Johnson, T. Eissenberg, M.L. Stitzer, E.C. Strain, I.A. Liebson, and G.E. Bigelow. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40: 17-25 (1995).
25. R.E.S. Bullingham, H.J. McQuay, and R.A. Moore. Clinical pharmacokinetics of narcotic agonist-antagonist drugs. Clin. Pharmacokinet. 8: 332-43 (1983).
26. nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc., L. Harris, Ed., U.S. Department of Health and Human Services, Rockville, MD. Natl. Inst. Drug Abuse Res. Monogr. Ser. 105: 569 (1991).